Saulsbury F T
Department of Pediatrics, University of Virginia Health Sciences Center, Charlottesville 22908.
Clin Exp Rheumatol. 1992 Nov-Dec;10(6):617-20.
High dose intravenous immunoglobulin (IVIG) is extremely effective therapy for Kawasaki syndrome (KS), but the mechanism of action remains unknown. The present study was performed to determine the effect of IVIG on lymphocyte populations and lymphocyte activation markers in 15 children with KS. Following IVIG, there was a decrease in the percentage of CD19 cells and an increase in the percentage of CD8 cells, but there was no change in the proportion of CD3 or CD4 cells. Moreover, there was no change in the percentage of activated CD4 or CD8 cells, as measured by HLA DR and interleukin-2 receptor expression after IVIG therapy. These results indicate that IVIG is effective treatment for KS via mechanisms other than the direct modulation of T cell activation markers.
大剂量静脉注射免疫球蛋白（IVIG）是治疗川崎病（KS）的极其有效的疗法，但其作用机制尚不清楚。本研究旨在确定IVIG对15例KS患儿淋巴细胞群体和淋巴细胞活化标志物的影响。静脉注射免疫球蛋白后，CD19细胞百分比下降，CD8细胞百分比增加，但CD3或CD4细胞比例没有变化。此外，通过静脉注射免疫球蛋白治疗后HLA-DR和白细胞介素-2受体表达测定，活化的CD4或CD8细胞百分比没有变化。这些结果表明，静脉注射免疫球蛋白是通过直接调节T细胞活化标志物以外的机制有效治疗川崎病。
